Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Allogene Therapeutics, Inc. (ALLO)

11.51   0.11 (0.96%) 07-02 16:58
Open: 11.37 Pre. Close: 11.4
High: 11.62 Low: 11.13
Volume: 1,496,752 Market Cap: 1,653(M)
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 11.64 - 11.7 11.7 - 11.75
Low: 10.86 - 10.93 10.93 - 10.99
Close: 11.27 - 11.38 11.38 - 11.49

Technical analysis

as of: 2022-07-01 4:19:58 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 14.59     One year: 17.05
Support: Support1: 9.35    Support2: 7.4
Resistance: Resistance1: 12.5    Resistance2: 14.59
Pivot: 10.96
Moving Average: MA(5): 11.55     MA(20): 10.64
MA(100): 9.02     MA(250): 14.97
MACD: MACD(12,26): 0.8     Signal(9): 0.8
Stochastic oscillator: %K(14,3): 76.2     %D(3): 77.1
RSI: RSI(14): 61.9
52-week: High: 27.86  Low: 6.42
Average Vol(K): 3-Month: 2,286 (K)  10-Days: 3,115 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ALLO ] has closed below upper band by 37.7%. Bollinger Bands are 61.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 16 days. This is a sign that the current trend might continue.

Headline News

Sat, 02 Jul 2022
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat

Thu, 30 Jun 2022
Allo cuts ribbon in Kearney, starts with test customers in July - KSNB

Mon, 27 Jun 2022
Allo-HSCT: Unrelated, Haploidentical Donations May Yield Similar Outcomes - Hematology Advisor

Fri, 24 Jun 2022
Chicago Fire season 11: Will Andy Allo return as Wendy Seager? - One Chicago Center

Wed, 22 Jun 2022
Owen N. Witte Sells 10,000 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) Stock - MarketBeat

Sun, 12 Jun 2022
Allogene Therapeutics (ALLO) Stock Price: $11 Target From Baird - Pulse 2.0

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 143 (M)
Shares Float 82 (M)
% Held by Insiders 31.1 (%)
% Held by Institutions 63.1 (%)
Shares Short 17,760 (K)
Shares Short P.Month 15,230 (K)

Stock Financials

EPS -1.88
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 6.8
Profit Margin (%) 0
Operating Margin (%) -664.6
Return on Assets (ttm) -14.2
Return on Equity (ttm) -25.8
Qtrly Rev. Growth 0
Gross Profit (p.s.) -1.28
Sales Per Share 0.27
EBITDA (p.s.) -1.73
Qtrly Earnings Growth 0
Operating Cash Flow -185 (M)
Levered Free Cash Flow -133 (M)

Stock Valuations

PE Ratio -6.13
PEG Ratio -2.7
Price to Book value 1.69
Price to Sales 42.61
Price to Cash Flow -8.88

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.